183 related articles for article (PubMed ID: 37873628)
1. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
[TBL] [Abstract][Full Text] [Related]
2. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
3. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria.
Kim JS; Lee JW; Kim BK; Lee JH; Chung J
Korean J Hematol; 2010 Dec; 45(4):269-74. PubMed ID: 21253430
[TBL] [Abstract][Full Text] [Related]
4. [Eculizumab in patients with paroxysmal nocturnal hemoglobinuria: a real-world study in China].
Wang LY; Hu QL; Chen M; Yang C; Han B
Zhonghua Xue Ye Xue Za Zhi; 2024 Feb; 45(2):184-189. PubMed ID: 38604796
[No Abstract] [Full Text] [Related]
5. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
6. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network.
Füreder W; Sperr WR; Heibl S; Zebisch A; Pfeilstöcker M; Stefanzl G; Jäger E; Greiner G; Schwarzinger I; Kundi M; Keil F; Hoermann G; Bettelheim P; Valent P
Ann Hematol; 2020 Oct; 99(10):2303-2313. PubMed ID: 32856141
[TBL] [Abstract][Full Text] [Related]
8. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
9. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Dührsen U; Risitano AM; Schubert J; Luzzatto L; Schrezenmeier H; Szer J; Brodsky RA; Hill A; Socié G; Bessler M; Rollins SA; Bell L; Rother RP; Young NS
Blood; 2007 Dec; 110(12):4123-8. PubMed ID: 17702897
[TBL] [Abstract][Full Text] [Related]
10. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
11. Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation.
Wang HC; Kuo CY; Liu IT; Chen TY; Chang YH; Lin SJ; Cho SF; Liu YC; Liu TC; Lin SF; Chang CS
Kaohsiung J Med Sci; 2017 Aug; 33(8):405-410. PubMed ID: 28811010
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.
Jang JH; Kim JS; Yoon SS; Lee JH; Kim YK; Jo DY; Chung J; Sohn SK; Lee JW
J Korean Med Sci; 2016 Feb; 31(2):214-21. PubMed ID: 26839475
[TBL] [Abstract][Full Text] [Related]
13. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
14. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
15. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
[TBL] [Abstract][Full Text] [Related]
16. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
17. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
Nishimura JI
Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
[TBL] [Abstract][Full Text] [Related]
18. Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry.
Villegas A; Núñez R; Gaya A; Cuevas-Ruiz MV; Bosch JM; Carral A; Arrizabalaga B; Gómez-Roncero MI; Mora A; Bravo P; Lavilla E; Monteserín C; Hernández B; Martínez-Barranco P; Jarque I; Urquía MA; García-Donas G; Brunet S; González FA; Urbano Á
Ann Hematol; 2017 Oct; 96(10):1727-1733. PubMed ID: 28748287
[TBL] [Abstract][Full Text] [Related]
19. Nationwide study of paroxysmal nocturnal hemoglobinuria in South Korea: paradox of eculizumab.
Kang KW; Moon H; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Kim BS; Lee J; Park Y
Ann Hematol; 2020 Jul; 99(7):1493-1503. PubMed ID: 32542443
[TBL] [Abstract][Full Text] [Related]
20. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
Schrezenmeier H; Röth A; Araten DJ; Kanakura Y; Larratt L; Shammo JM; Wilson A; Shayan G; Maciejewski JP
Ann Hematol; 2020 Jul; 99(7):1505-1514. PubMed ID: 32390114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
